EICHOR
● Recruiting
Suramin for the Treatment of Autism Trial: KZ101 in a Male Pediatric Population With Autism Spectrum Disorder (ASD)
Condition: Autism Spectrum Disorder (ASD) · Sponsor: Children's Hospital of Orange County
About this study
Suramin has been found to correct the symptoms, metabolism, and brain synaptic abnormalities in two classical genetic and environmental mouse models of autism. A preliminary clinical trial (SAT-1) examined the safety and activity of a single low-dose of suramin in children with ASD and concluded suramin showed promise as a novel approach to treatment of ASD. The current study, STAT-2A, will be a randomized, double-blind, crossover, 30-week study to evaluate the preliminary proof of concept, safety, and PK of suramin sodium (KZ101) with repeat dosing by IV infusion in males 5-14 years of age who have been diagnosed with ASD. The study will be conducted at approximately 3 sites contributing approximately 15 subjects per site. Total enrollment of approximately 45 subjects is planned to achieve approximately 36 participants completing the study.
This description comes directly from the study's public registry record.
Talk to the study team
Adrienne Moore, PhD · 714-288-7456 · adrienne.moore@choc.org
Always discuss trial participation with your own doctor first.
Locations (2)
| Children's Hospital Orange County, Thompson Autism and Neurodevelopmental Center | Orange, California, United States | Recruiting |
| Kennedy Krieger Institute | Baltimore, Maryland, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.